Laboratories that use revised carbapenem breakpoints detect significantly more carbapenem-resistant Enterobacteriaceae than laboratories that use historical ones.
Laura Waters, MD, FRCP, a consultant physician in the GU and HIV Division at Mortimer Market Center, explains why it is too soon to label the remission as a cure.
Paul Sax, MD, clinical director in the Division of Infectious Diseases at Brigham and Women's Hospital, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.
.png)
